Abstract
Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Keywords: Cancer, genes, parkinson’s disease, pathways.
Current Cancer Drug Targets
Title:Genetic Predisposition to Parkinson’s Disease and Cancer
Volume: 14 Issue: 3
Author(s): Zhiming Li, Qing Lin, Qilin Ma, Congxia Lu and Chi-Meng Tzeng
Affiliation:
Keywords: Cancer, genes, parkinson’s disease, pathways.
Abstract: Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Export Options
About this article
Cite this article as:
Li Zhiming, Lin Qing, Ma Qilin, Lu Congxia and Tzeng Chi-Meng, Genetic Predisposition to Parkinson’s Disease and Cancer, Current Cancer Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1568009614666140312145936
DOI https://dx.doi.org/10.2174/1568009614666140312145936 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals
Current Pharmaceutical Design Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Subject Index To Volume 6
Anti-Cancer Agents in Medicinal Chemistry Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine Genetic Profile of SNP(s) and Ovulation Induction
Current Pharmaceutical Biotechnology A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis
Current Topics in Medicinal Chemistry Formulation and Evaluation of Polymeric Nanomicelles of Gliptin for Controlled Drug Delivery
Drug Delivery Letters Synthesis and Biological Activity of 3-N-Substituted Estrogen Derivatives as Breast Cancer Agents
Mini-Reviews in Medicinal Chemistry Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy An Antileukemic Glutaminase Free L-Asparaginase from Bacillus brevis
Current Biotechnology What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Biomarkers for Colorectal Cancer: Identification Through Proteomics
Current Proteomics Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme
Anti-Cancer Agents in Medicinal Chemistry Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets